Sheba Healthspan Research Population (SHARP) Trial - Sheba Longevity Center Diagnostic and Intervention Protocol to Lower Biological Age in Older Adults
NCT07596576 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1500
Last updated 2026-05-19
Summary
Background: Population aging is accelerating rapidly in Israel and worldwide, necessitating adaptation of the healthcare system and considering new approaches that serve the needs of older adult populations.
Working hypothesis and aims: We hypothesize that a personalized health and behavior intervention program will decrease the biological age as assessed by several biological aging clocks and improve functional and cognitive performance among older adults.
Methods: We propose to conduct a randomized study among healthy community-dwelling elderly subjects (\>50 years old). The study will include an extensive aging assessment and imaging protocol (baseline assessment), including comprehensive physical, functional, sensory, cognitive, and mental assessment. Each participant in the intervention group will receive a personalized intervention program based on an integrative systems approach analysis. In addition, a uniquely developed application will track compliance and monitor physiological data through a provided wearable device. The control group will be assessed at baseline without receiving an intervention program. Each participant will visit the center aging after 6 months for a blood test and after 12 months for a second extensive diagnostic protocol, similar to the baseline assessment protocol. About 1,500 subjects will be recruited to participate in the study.
Expected results: Obtaining data at two points will allow us to examine efficiency and compliance with a personalized intervention program based on integrative systems analysis models. We expect biological age, general well-being, and various clinical and psychosocial outcomes in the intervention group will decrease and improve compared to the control group.
Study importance and relevance: The obtained results may help establish evidence-based healthy aging diagnostics protocols and an effective personalized intervention program that might be applied, with proper modifications, to national healthcare organizations for the general older adult population. In addition, to provides a scientific basis on which policymakers and intervention programs can rely to develop national guidelines for promoting extended health.
Conditions
- Healthy Aging
- Healthspan
- Biological Age
- Intrinsic Capacity
- Immunaging
Interventions
- OTHER
-
healthspan personalized protocol
The study will include an extensive aging assessment and imaging protocol (baseline assessment), including comprehensive physical, functional, sensory, cognitive, and mental assessment. Each participant in the intervention group will receive a personalized intervention program based on an integrative systems approach analysis. In addition, a uniquely developed application will track compliance and monitor physiological data through a provided wearable device. Each participant will visit the center aging after 6 months for a blood test and after 12 months for a second extensive diagnostic protocol, similar to the baseline assessment protocol.
- OTHER
-
Control
The control group will be assessed at baseline without receiving an intervention program. Each participant will visit the center aging after 6 months for a blood test and after 12 months for a second extensive diagnostic protocol, similar to the baseline assessment protocol.
Sponsors & Collaborators
-
Sheba Medical Center
lead OTHER_GOV
Principal Investigators
-
Evelyne Bischof, MD PhD · Sheba Medical Center
-
Abigail Goshen, PhD · Sheba Medical Center
-
Tzipi Strauss, MD · Sheba Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-03-01
- Primary Completion
- 2027-03-01
- Completion
- 2027-12-01
Countries
- Israel
Study Locations
More Related Trials
-
A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex
NCT01285596 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy Participants
NCT05753592 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
NCT07269301 ·Status: RECRUITING ·Phase: PHASE1
-
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
NCT06535399 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
NCT04634149 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Pharmacodynamics Comparison Study Between Two Pegfilgrastim Formulations
NCT02589301 ·Status: COMPLETED ·Phase: PHASE1
-
A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT01631097 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
NCT06928779 ·Status: COMPLETED ·Phase: PHASE1
-
GSK1349572 Relative Bioavailability Study
NCT01098513 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
NCT03465059 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers
NCT02528903 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Seltorexant in Healthy Participants
NCT04553042 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects
NCT06094790 ·Status: COMPLETED ·Phase: PHASE1
-
Comparative Pharmacokinetic Study of Aprepitant Injection in Humans
NCT06226506 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Bioequivalence Study of L04TD2 Compared to Administration of L04RD1 in Healthy Volunteers
NCT05581693 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)
NCT02385851 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.
NCT05976373 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Pharmacokinetics and Safety of Miricorilant
NCT07553663 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
NCT07165002 ·Status: RECRUITING ·Phase: PHASE1
-
Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers
NCT06141889 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT04772612 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869
NCT00733187 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants
NCT05976360 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
NCT04584710 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2